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Genome-wide association studies (GWASs) of follicular lymphoma (FL) have previously identified human leukocyte antigen (HLA) gene
variants. To identify additional FL susceptibility loci, we conducted a large-scale two-stage GWAS in 4,523 case subjects and 13,344 con-
trol subjects of European ancestry. Five non-HLA loci were associated with FL risk: 11q23.3 (rs4938573, p ¼ 5.79 3 1020) near CXCR5;
11q24.3 (rs4937362, p¼ 6.763 1011) near ETS1; 3q28 (rs6444305, p¼ 1.103 1010) in LPP; 18q21.33 (rs17749561, p¼ 8.283 1010)
near BCL2; and 8q24.21 (rs13254990, p¼ 1.063 108) near PVT1. In an analysis of the HLA region, we identified four linked HLA-DRb1
multiallelic amino acids at positions 11, 13, 28, and 30 that were associated with FL risk (pomnibus¼ 4.203 1067 to 2.673 1070). Addi-
tional independent signals included rs17203612 in HLA class II (odds ratio [ORper-allele] ¼ 1.44; p ¼ 4.593 1016) and rs3130437 in HLA
class I (ORper-allele¼ 1.23; p¼ 8.233 109). Our findings further expand the number of loci associated with FL and provide evidence that
multiple common variants outside the HLA region make a significant contribution to FL risk.Follicular lymphoma (FL [MIM 613024]) is a common B
cell malignancy characterized by a variable indolent clin-
ical course that can take decades to manifest and, in
some cases, can be followed by transformation to aggres-
sive diffuse large B cell lymphoma (DLBCL).1,2 The previ-
ous genome-wide association studies (GWASs) of relatively
small sample sizes have revealed FL susceptibility loci in
the human leukocyte antigen (HLA) class I and class II re-
gions on 6p21.32-33.3–7 To identify new FL susceptibility
loci, we genotyped 2,301 FL case subjects and 2,854 con-
trol subjects of European descent from 22 studies (NCI FL
GWAS) as part of a larger initiative using the Illumina
OmniExpress Beadchip (Table S1; Figure S1 available on-
line). All studies obtained informed consent from partici-
pants and approval from the respective Institutional
Review Boards for this study. Cases were ascertained from
cancer registries, clinics, or hospitals or through self-report
verified by medical and pathology reports (Table S1). The
phenotype information for all cases was reviewed centrally
at the International Lymphoma Epidemiology Con-
sortium (InterLymph) Data Coordinating Center, and
cases were classified according to the proposed scheme
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(2008) (Table S1). Genotypes were called using Illumina
GenomeStudio software, and quality-control duplicates
showed >99% concordance. All initial data analyses and
management were conducted using the Genotyping Li-
brary and Utilities (GLU), and extensive quality-control
metrics were applied to the data. Specifically, monomor-
phic SNPs and SNPs with call rates <93% were removed,
and samples with call rates %93%, mean heterozygosity
<0.25 or >0.33 based on the autosomal SNPs, or gender
discordance (>5% heterozygosity on the X chromosome
for males and <20% heterozygosity on the X chromosome
for females) were excluded. Unexpected duplicates
(>99.9% concordance) and first-degree relatives on the
basis of identity-by-descent sharing with Pi-hat >0.40
were removed. Ancestry was assessed using the GLU struc-
t.admix module, and participants with <80% European
ancestry were also excluded (Figure S2). After these qual-
ity-control steps, 94% of the participants and 611,844
SNPs remained for analysis (Tables S2 and S3). Genotype
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Table 1. Association Results for Loci and SNPs Associated with Risk of Follicular Lymphoma
Chr
Nearest
Gene(s) SNP Positiona
Risk
Alleleb
Other
Allele RAFc Stage OR (95% CI) p Phetd I2e
Known Locus
6p21.32 HLA region rs12195582
(rs115374828)
32444544 T C 0.465 NCI 1.88 (1.74–2.02) 3.26 3 1058 – –
0.498 previous GWAS 1.55 (1.33–1.80) 1.10 3 108
0.435 replication 1.75 (1.60–1.90) 1.17 3 1037
– combined 1.78 (1.69–1.88) 5.36 3 10100 2.75 3 101 19.56
Genome-wide Significant Loci
11q23.3 CXCR5 rs4938573 118741842 C T 0.204 NCI 1.30 (1.19–1.43) 5.97 3 109 – –
0.193 previous GWAS 1.37 (1.14–1.64) 0.0008
0.188 replication 1.39 (1.25–1.54) 3.17 3 1010
– combined 1.34 (1.26–1.43) 5.79 3 1020 7.69 3 101 0.00
11q24.3 ETS1 rs4937362 128492739 T C 0.456 NCI 1.16 (1.08–1.25) 7.01 3 105 – –
0.465 previous GWAS 1.33 (1.16–1.54) 5.90 3 105
0.467 replication 1.17 (1.08–1.28) 0.0002
– combined 1.19 (1.13–1.25) 6.76 3 1011 7.52 3 101 0.00
3q28 LPP rs6444305 188299902 G A 0.276 NCI 1.16 (1.08–1.27) 0.0002 – –
0.269 previous GWAS 1.30 (1.06–1.59) 0.01
0.281 replication 1.25 (1.14–1.37) 2.21 3 106
– combined 1.21 (1.14–1.28) 1.10 3 1010 4.42 3 101 0.00
18q21.33 BCL2 rs17749561 60783211 G A 0.910 NCI 1.43 (1.25–1.61) 2.18 3 107 – –
0.908 previous GWAS 1.23 (0.96–1.57) 1.10 3 101
0.905 replication 1.28 (1.10–1.49) 0.002
– combined 1.34 (1.22–1.47) 8.28 3 1010 5.43 3 102 49.37
8q24.21 PVT1 rs13254990 129076451 T C 0.315 NCI 1.20 (1.11–1.30) 8.39 3 106 – –
0.307 previous GWAS 1.15 (0.98–1.34) 0.08
0.315 replication 1.16 (1.06–1.27) 0.001
– combined 1.18 (1.11–1.24) 1.06 3 108 6.99 3 101 0.00
Suggestive Loci
17q25.3 C17orf62 rs3751913 80405552 C T 0.121 NCI 1.25 (1.11–1.39) 0.0001 – –
0.126 previous GWAS 1.42 (1.16–1.75) 0.0008
0.121 replication 1.14 (1.01–1.29) 0.04
– combined 1.23 (1.14–1.33) 2.24 3 107 2.59 3 101 21.50
3q13.33 CD86 rs2681416 121817613 A G 0.311 NCI 1.24 (1.15–1.35) 6.73 3 108 – –
0.305 previous GWAS 1.15 (0.99–1.34) 0.06
0.329 replication 1.06 (0.97–1.15) 0.23
– combined 1.16 (1.09–1.22) 2.33 3 107 5.54 3 104 72.83
18q12.3 SLC14A2 rs11082438 42865210 G T 0.936 NCI 1.39 (1.18–1.61) 4.65 3 105 – –
0.941 previous GWAS 1.46 (1.07–1.99) 0.02
0.935 replication 1.22 (1.02–1.46) 0.03
– combined 1.33 (1.19–1.48) 4.01 3 107 9.26 3 101 0.00
aPosition according to human reference NCBI37/hg19.
bAllele associated with an increased risk of FL.
cRisk allele frequency in controls.
dCochran’s Q test heterogeneity p value.
eI2 heterogeneity index.
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ated Locus rs4938573 in 11q23.3
Figure shows the association results from
the NCI FL GWAS and stages 1 and 2 com-
bined (red diamond), recombination hot-
spots, and LD plots.also included, resulting in a total of 2,142 FL case subjects
and 6,221 control subjects for analysis (NCI FL GWAS;
Table S4).
To evaluate population substructure, a principal compo-
nents analysis was conducted using the GLU struct.pca
module. Plots of the top principal components are shown
in Figure S3. Association testing was conducted assuming
a log-additive genetic model adjusted for age, sex, and sig-
nificant principal components. A quantile-quantile plot
of the association results revealed an enrichment of
SNPs with small p values even after removal of all SNPs
in the HLA region, which has been previously reported
to be associated with FL (lambda ¼ 1.018, Figure S4). In
addition to the HLA region, one locus on 11q23.3 reached
genome-wide statistical significance (p < 5 3 108)
(Figure S5).
To increase power to detect associations in stage 1, we
added data on 586 FL case subjects and 1,537 control sub-
jects from two independent previously published GWASs
(UCSF24 and SCALE3) to the newly genotyped NCI FL
GWAS (Tables S1 and S4; Figure S1). Because different gen-
otyping platforms were used (Table S2), we imputed all
three GWASs (NCI, UCSF2, SCALE) using the 1000
Genomes Project (1kGP) v.3 (March 2012 release) refer-
ence panel9 and IMPUTE2.10 The genotype data under-
went rigorous quality control filters before imputationThe American Journal of Human Ge(Table S2), and association testing
was conducted separately for each
study using SNPTEST v.2 adjusted
for age, sex, and significant principal
components.
Association results from the NCI FL
GWAS and the two previously geno-
typed GWASs (totaling 2,728 case
subjects, 7,758 control subjects in
stage 1) were analyzed in a meta-anal-
ysis using a fixed-effects inverse-vari-
ancemethod based on the b estimates
and standard errors from each study.
Only SNPs with information scores
>0.3 were included in the meta-
analysis. In the stage 1 meta-analysis,
we identified three non-HLA loci
(11q23.3, 11q24.3, and 3q13.33)
that reached genome-wide signifi-
cance (p < 5 3 108). To confirm
these loci and discover additional
loci, 11 non-HLA SNPs with p < 5 3
106 from the stage 1 meta-analysis
were chosen for replication in stage 2. Only SNPs with a
MAF > 1% were considered for replication, and no SNPs
were taken forward for replication in regions where they
appeared to be singletons or obvious artifacts. Stage 2 repli-
cation was undertaken in a new set of 1,795 FL case sub-
jects and 5,586 control subjects, which included 119 case
subjects and 349 control subjects from another GWAS
(UCSF1/NHS) genotyped on the OmniExpress microarray
and imputed using IMPUTE210 and the 1kGP data,9 and
1,676 cases and 5,237 controls with de novo genotyping
(Tables S1, S2, and S4). All 11 SNPs were either directly
genotyped or had a high imputation information score
(average information score ¼ 0.92). Genotyping of these
11 SNPs by TaqMan (Applied Biosystems) in 470 subjects
from the NCI GWAS yielded >88.9% concordance with
the imputed dosages (median concordance¼ 99.6%), indi-
cating that imputation accuracy was high. Association
testing was conducted for each study using either GLU
(de novo genotyping) or SNPTEST (UCSF1/NHS), adjusting
for relevant factors.
Results from the stage 1 and 2 studies were then meta-
analyzed using a fixed effects model. In the combined
meta-analysis, we found five non-HLA loci that achieved
genome-wide significance (p < 5 3 108) at 11q23.3
(rs4938573, p ¼ 5.79 3 1020), 11q24.3 (rs4937362, p ¼
6.76 3 1011), 3q28 (rs6444305, p ¼ 1.10 3 1010),netics 95, 462–471, October 2, 2014 465
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Figure shows the association results from
the NCI NHL GWAS and stages 1 and 2
combined (red diamond), recombination
hotspots, and LD plots.18q21.33 (rs17749561, p ¼ 8.28 3 1010), and 8q24.21
(rs13254990, p ¼ 1.06 3 108); and three suggestive loci
(p < 5 3 107) at 17q25.3 (rs3751913, p ¼ 2.24 3 107),
3q13.33 (rs2681416, p ¼ 2.33 3 107), and 18q12.3
(rs11082438, p ¼ 4.01 3 107) (Table 1). Two of the
five loci that reached genome-wide significance in the
stage 1 and 2 meta-analysis (11q23.3 and 11q24.3) were
genome-wide significant in the stage 1 meta-analysis and
were robustly replicated in stage 2 (p ¼ 3.17 3 1010 and
p ¼ 0.0002, respectively). The remaining three loci
achieved genome-wide significance after inclusion of the
stage 2 data and therefore would benefit from further vali-
dation in other independent samples.
rs4938573 at 11q23.3 maps 12.6 kb upstream of the
chemokine (c-x-c motif) receptor 5 gene (CXCR5 [MIM
601613]) (Figure 1). The 11q24.3 locus marked by
rs4937362 (p ¼ 6.76 3 1011) is approximately 35 kb
upstream of v-ets avian erythroblastosis virus E26 onco-
gene homolog 1 (ETS1 [MIM 164720]) (Figure 2). The
3q28 locus marked by rs6444305 maps to a region that
overlaps the LIM domain containing preferred transloca-
tion partner in lipoma (LPP [MIM 600700]) and is
836.4 kb upstream of BCL6 (MIM 109565) (Figure 3).
rs17749561 in 18q21.33 is located 7.4 kb downstream
of the antiapoptotic oncogene, B cell CLL/lymphoma 2
(BCL2 [MIM 151430]) (Figure 4); and rs13254990 at466 The American Journal of Human Genetics 95, 462–471, October 2, 20148q24.21 maps near the oncogene,
plasmacytoma variant translocation
1 gene (PVT1 [MIM 165140]) (Fig-
ure 5). Characteristics of these loci
are presented in Table S5. The sug-
gestive SNP rs3751913 is in chromo-
some 17 opening reading frame 62
(C17orf62); rs2681416 is in CD86
molecule (CD86) (MIM 601020); and
rs11082438 is in solute carrier 14A2
(SLC14A2 [MIM 601611]) (Table 1,
Figure S6). Using the Cochran’s Q
test and by estimating the I2 heteroge-
neity index, no substantial heteroge-
neity was observed among the studies
for any SNP (pheterogeneity R 0.05)
except for the suggestive locus,
rs2681416 at 3q13.33 (Table 1).
Although the p value for heterogene-
ity for rs13254990 was borderline
significant, all of the effect esti-
mates for the individual studies were
above 1.0.To explore potential functional roles for associated SNPs
and their surrogates (r2 > .80) and to assess the B cell-spe-
cific chromatin dynamics of regions overlapping with the
associated SNPs, we conducted HaploReg11 and ChroMoS
analyses.12,13 Here we found that three loci, 11q23.3,
3q13.33, and 8q24.21, were annotated as overlapping
enhancers in the lymphoblastoid cell line GM12878,14
suggesting that our GWAS signals map to variants that
overlap within regions of active chromatin state in B cells
(Table S6; Figure S7). However, an expression quantitative
trait loci (eQTL) analysis using publicly available RNA
sequencing data on lymphoblastoid cell lines (available
from the Gene Expression Omnibus [GEO] repository
under accession number GSE16921) yielded no notable
(FDR < 0.05) associations of the selected SNPs with gene
expression levels. Additional analysis using microarray
data (GEO accession number GSE8052) did not reveal
any significant eQTL associations for the genome-wide
significant loci, although the suggestive SNP, rs3751913,
was associated with C17orf62 expression (data not
shown). Thus, further work is needed to identify and
characterize the biological basis of these FL susceptibility
alleles.
Consistent with previous smaller reports, the strongest
effects on FL risk were observed in the HLA region at
6p21.32-33, where 8,104 SNPs achieved genome-wide
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spots, and LD plots.significance (p < 5 3 108) in the stage 1 meta-analysis
(Figure S8). One top SNP, rs12195582, was carried forward
for replication in stage 2 and reached a combined p ¼
5.36 3 10100 in stages 1þ2 (Table 1). To further refine
the association of HLA variants with FL risk and determine
whether specific coding variants within HLA genes
contributed to the diverse association signals, we imputed
classical HLA alleles and amino acids (AAs) at seven loci
(HLA-A [MIM 142800], HLA-B [MIM 142830], HLA-C
[MIM 142840], HLA-DQA1 [MIM 146880], HLA-DQB1
[MIM 604305], HLA-DRB1 [MIM 142857], and HLA-
DPB1 [MIM 142858]) on the four GWAS data sets from
stages 1þ2 (NCI, USCF2, SCALE, UCSF1/NHS) using
SNP2HLA15 and a reference panel from the Type 1 Diabetes
Genetics Consortium (T1DGC) consisting of genotype
data from 5,225 individuals of European descent that
were typed for classical HLA alleles. The imputation accu-
racy of HLA types was high (>95.23%) when compared
to HLA sequencing data on a subset of NCI and UCSF2
samples scanned as part of this study.16,17 Due to the
limited number of SNPs (7,253) in the T1DGC reference
set, imputation of HLA SNPs was conducted with IMPUTE2
and the 1kGP reference set. A total of 68,488 SNPs, 201
classical HLA alleles (two- and four-digit resolution), and
1,038 AA markers including 103 AA positions that wereThe American Journal of Human Ge‘‘multiallelic’’ with three to six
different residues present at each
position, were successfully imputed
(information score > 0.3 for SNPs
or r2 > 0.3 for alleles and AAs) and
available for downstream analysis.
Association testing was conducted
using PLINK,18 where multiallelic
markers were analyzed as binary
markers (e.g., allele present or ab-
sent). A meta-analysis was conducted
where we tested SNPs, HLA alleles,
and AAs across the HLA region for as-
sociation to FL. Among the imputed
AAs and HLA alleles tested, the top
associated signal mapped to a DRb1
AA at position 28 that carries three
possible amino acids: Glu, Asp, and
His. Asp was associated with low
(OR ¼ 0.53; p ¼ 6.1 X 1072) and
Glu with high (OR ¼ 1.86; p ¼
7.99 3 1069) FL risk (Table S7).
Global omnibus tests of position 28
(2.49 3 1067 % p % 3.84 3 1067)
and other nearby DRb1 AA positions at 11, 13, and 30
yielded statistically similar associations with FL risk (Table
S9). These results support the previously reported associa-
tion between FL and DRb1 position 13 in a small study
of Europeans.19 However, due to the high LD between po-
sitions 11, 13, 28, and 30, we were unable to determine the
significance of one position at the exclusion of the other
through reciprocal conditional analyses. The most signifi-
cant imputed two- or four-digit HLA allele in our analysis
was DRB1*01 (OR ¼ 1.85; p ¼ 2.573 1042) (Table S7), en-
coded by Glu28, Cys30, Phe13, and Leu11 (Table S9). An
association with FL risk was found for HLA-DRB1*07:01
that is also encoded by residues at 11, 13, 28, and 30
(p ¼ 1.59 3 1020) (Table S9). Positions 11, 13, 28, and
30 reside in the middle of the HLA-DR heterodimer mole-
cule in the peptide binding cleft (Figure S9) that specif-
ically impact binding pockets 4, 6, and 7. These are key
peptide binding anchors in DRb120 that influence binding
preferences of alleles,21 suggesting an important role for
DRb1 peptide presentation in follicular lymphomagenesis.
To identify independent HLA variants controlling for
DRb1 28 (used as a surrogate for the 11, 13, 28, and 30
group), we included all genotyped and imputed HLA
SNPs, AAs, and alleles in a forward stepwise analysis. The
most significant variant after controlling for DRb1 28 wasnetics 95, 462–471, October 2, 2014 467
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ated Locus rs17749561 in 18q21.33
Figure shows the association results from
the NCI FL GWAS and stages 1 and 2 com-
bined (red diamond), recombination hot-
spots, and LD plots.rs17203612 (p ¼ 4.59 3 1016), an intergenic SNP 39.2 kb
and 99.7 kb downstream of HLA-DRA (MIM 142860) and
HLA-DRB1, respectively (Figure 6; Table S10). A conditional
analysis on DRb1 28 and rs17203612 revealed that the
next most statistically significant variant was rs3130437
(p ¼ 8.23 3 109) located 15.6 kb downstream of HLA-C
in HLA class I (Figure 6; Table S10). After controlling for
DRb1 28, rs17203612, and rs3130437, no additional sig-
nals with p < 5 3 108 were observed (Figure 6). Of note,
we did see a residual signal (p ¼ 8.18 3 106) at the func-
tionally relevant DPb1 Glu84 position,22 a reported risk
locus for Hodgkin lymphoma.23 A conditional analysis of
DRb1 28, rs17203612, and rs3130437 eliminated the
majority of residual effects for the previously reported
HLA SNPs and alleles associated with FL (Table S11).
We conducted a series of preliminary bioinformatics
analyses to explore the potential functional relevance of
rs17203612 and rs3130437 using publicly available RNA
sequencing expression and methylation data and found
significant (FDR < 0.05) gene expression and methylation
differences associated with rs17203612- and rs3130437-
linked SNPs (Tables S12 and S13). Specifically, we found
significant gene expression changes associated with
rs12194148, a proxy for rs17203612, in class II (HLA-
DRB5 [MIM 604776], HLA-DRB6, HLA-DRB1, HLA-DQB1,
HLA-DQB2 [MIM 615161], HLA-DQA1, HLA-DQA2 [MIM468 The American Journal of Human Genetics 95, 462–471, October 2, 2014613503], BTNL2 [MIM 606000],
C6orf25); and with rs3130439, a
proxy for rs3130437, in HLA class I
(PSORS1C2, PSORS1C3, DPCR1 [MIM
613928]) (Table S12). Of note, ten
of the rs17203612-linked SNPs that
showed correlation with higher
HLA-DQB1 expression also showed
correlation with lower HLA-DQB1
methylation levels (Table S12) that
further supports the potential role
of HLA class II FL-associated SNPs
in HLA-DQB1 regulation.24,25 Addi-
tional eQTL analyses using micro-
array data also suggested potential
eQTL associations with HLA-C,
TCF19 (MIM 600912), and HLA-B
expression (Table S14). However, we
did not observe significant enrich-
ment of particular regulatory markers
within these associated regions,
although overlap with some regulato-
ry signals was observed (Table S15).In summary, our study identified five non-HLA suscepti-
bility alleles that were robustly associated with FL risk.
Moreover, our work highlights the important role of HLA
structural variants and regulatory SNPs in the etiology of
FL, advances the catalog of HLA and non-HLA genetic var-
iants associated with FL risk, and provides further evidence
for a role of DRb1 peptide presentation in FL. Functional
studies will be required to elucidate the biological basis
of these loci and to determine their role in follicular
lymphomagenesis.Supplemental Data
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